Research Topics
| Elaine HylekSummaryAffiliation: Boston University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Anticoagulation therapy for atrial fibrillationElaine M Hylek
Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
Semin Thromb Hemost 39:147-52. 2013..Translating the efficacy of clinical trials into effective use of these novel agents in clinical practice will require an understanding of their pharmacokinetic profiles, dose selection, and management in select clinical situations...
Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvementElaine M Hylek
Department of Medicine, Boston University Medical Center, Boston, MA 02118, USA
J Thromb Thrombolysis 35:333-5. 2013..Targeted strategies to improve TTR are urgently needed...
DU-176b, an oral, direct Factor Xa antagonistElaine Hylek
Boston University Medical Center, Department of Medicine, 91 East Concord Street, Suite 200, Boston, MA 02118, USA
Curr Opin Investig Drugs 8:778-83. 2007..By January 2005, phase II studies had begun in the US and Europe, and by March 2006, phase II studies had begun in Japan. Phase II trials for the prevention of thromboembolism were ongoing in mid 2007...
Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillationElaine M Hylek
Department of Medicine, Boston University School of Medicine, MA 02118, USA
Stroke 37:1075-80. 2006..In addition to baseline characteristics, we sought to define the physician-cited reason for not prescribing warfarin for each patient...
Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillationElaine M Hylek
Research Unit-Section of General Internal Medicine and Clinical Epidemiology Unit, Boston University School of Medicine, 801 Massachusetts Avenue, 2nd Floor, Boston, MA 02118, USA
Thromb Haemost 100:16-7. 2008
Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF VElaine M Hylek
Department of Medicine, Research Unit, Section of General Internal Medicine, Boston University School of Medicine, Boston, MA 02118, USA
Stroke 39:3009-14. 2008..We sought to determine if differences in baseline characteristics, use of potentially risk-modifying medications, or anticoagulation control help to explain the lower risk of stroke among warfarin-treated patients in SPORTIF V...
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillationElaine M Hylek
Research Unit, Section of General Internal Medicine, Boston University School of Medicine, Boston Medical Center, 91 East Concord St, Suite 200, Boston, MA 02118, USA
Circulation 115:2689-96. 2007..We sought to define the tolerability of warfarin among an elderly inception cohort with atrial fibrillation...
The need for new oral anticoagulants in clinical practiceElaine M Hylek
Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118, USA
J Cardiovasc Med (Hagerstown) 10:605-9. 2009..As a result, there is a pressing need for convenient new, well-tolerated and effective oral anticoagulants that do not require frequent dose adjustment and routine coagulation monitoring...
Antithrombotic prophylaxis in elderly patients with atrial fibrillationElaine M Hylek
Department of Medicine, Research Unit Section of General Internal Medicine, Boston University Medical Center, Boston, Massachusetts 02118, USA
Semin Thromb Hemost 35:548-53. 2009..An understanding of the pathological changes that predispose to hemorrhage, hazards of polypharmacy, and factors that contribute to variability in dose response will facilitate a more informed use of these medications in clinical care...
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Jack Ansell
Department of Medicine, Boston University Medical Center, 88 East Newton Street, Boston, MA 02118, USA
Chest 133:160S-198S. 2008..Patient self-monitoring or self-management, however, is a choice made by patients and physicians that depends on many factors. We suggest that such therapeutic management be implemented where suitable (Grade 2B)...
Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly populationDavid Garcia
Department of Medicine, Division of General Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA
Chest 127:2049-56. 2005....
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyJack Ansell
Department of Medicine, Boston University Medical Center, 88 E Newton St, Boston, MA 02118, USA
Chest 126:204S-233S. 2004....
Measuring quality of oral anticoagulation care: extending quality measurement to a new fieldAdam J Rose
Center for Health Quality, Outcomes and Economic Research, Bedford VA Medical Center, Bedford, MA, USA
Jt Comm J Qual Patient Saf 35:146-55. 2009..Quality indicators provide a framework for quality improvement, two goals of which are to maximize the effectiveness of therapy and to minimize harm...
The risk of hemorrhage among patients with warfarin-associated coagulopathyDavid A Garcia
Department of Medicine, University of New Mexico, Albuquerque, New Mexico, USA
J Am Coll Cardiol 47:804-8. 2006..Among warfarin-treated patients with international normalized ratio (INR) >5, we sought to determine the risk of major bleeding within 30 days...
Epidemiology of subtherapeutic anticoagulation in the United StatesAdam J Rose
Center for Health Quality, Outcomes, and Economic Research, Bedford VA Medical Center, Bedford, MA 01730, USA
Circ Cardiovasc Qual Outcomes 2:591-7. 2009..Low international normalized ratio (INR; <or=1.5) increases risk for thromboembolism. However, little is known about the epidemiology of low INR...
Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA)Adam J Rose
Center for Health Quality, Outcomes, and Economic Research, Bedford VA Medical Center, 200 Springs Road, Bedford, MA 01730, USA
Circ Cardiovasc Qual Outcomes 4:22-9. 2011..Our objective was to profile site performance in the Veterans Health Administration (VA) using risk-adjusted percent time in therapeutic range (TTR)...
Effectiveness of warfarin among patients with cancerAdam J Rose
Department of Medicine, Research Unit Section of General Internal Medicine, Boston University School of Medicine, Boston Medical Center, Boston, MA 02118 2644, USA
J Gen Intern Med 22:997-1002. 2007..Is this also the case when cancer patients are anticoagulated for other indications?..
Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosisElaine M Hylek
General Medicine Division/Clinical Epidemiology Unit, Ninth Floor, Massachusetts General Hospital, 50 Staniford St, Boston, MA 02114, USA
Arch Intern Med 163:621-7. 2003..Strategies are needed to improve the overall quality of anticoagulant care, including the substitution of low-molecular-weight heparin for unfractionated heparin, where appropriate...
Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factorsElaine M Hylek
Harvard Medical School, General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
Semin Vasc Med 3:271-8. 2003....
Trends in anticoagulation management across community-based practices in the United States: the Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) studyElaine M Hylek
Department of Medicine, General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA 02114, USA
J Thromb Thrombolysis 16:83-6. 2003..This report describes the methodology and preliminary results. Analysis is ongoing, and full results will be reported in the future...
The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillationCarmella Evans Molina
Department of Medicine, Division of Endocrinology and Metabolism, University of Virginia, Charlottesville, Virginia, USA
J Am Geriatr Soc 55:1038-43. 2007..To compare prescription drug cost savings under the most commonly selected Medicare Part D prescription plan in 2006 with savings under the Medicare standard benefit and with drug costs assuming no coverage in an elderly cohort of patients...
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillationElaine M Hylek
General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
N Engl J Med 349:1019-26. 2003..0 or greater reduces not only the frequency of ischemic stroke but also its severity and the risk of death from stroke. Our findings provide further evidence against the use of lower INR target levels in patients with atrial fibrillation...
Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyAlan S Go
Division of Research, Kaiser Permanente of Northern California, Oakland, CA, USA
J Thromb Thrombolysis 15:41-6. 2003..Since atrial and venous pressures are similar, genetic variants that promote venous thromboembolism may increase the risk of atrial thrombi and subsequent stroke in atrial fibrillation...
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?Alan S Go
Division of Research, Kaiser Permanente of Northern California, Oakland, CA 94612, USA
JAMA 290:2685-92. 2003..Warfarin has been shown to be highly efficacious for preventing thromboembolism in atrial fibrillation in randomized trials, but its effectiveness and safety in clinical practice is less clear...
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillationMargaret C Fang
Division of General Internal Medicine, Hospitalist Group, University of California, San Francisco, San Francisco 94143, USA
Ann Intern Med 141:745-52. 2004..However, higher intensities increase hemorrhage risk. Optimal use of warfarin for atrial fibrillation requires precise information on the risk for intracranial hemorrhage as a function of patient age and anticoagulation intensity...
Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) studyMargaret C Fang
University of California, San Francisco, CA 94143, USA
Circulation 112:1687-91. 2005..We examined data from a large contemporary cohort of AF patients to address this question...
Antithrombotic therapy in atrial fibrillationDavid A Garcia
Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA
Clin Geriatr Med 22:155-66, x. 2006....
Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillationRobert G Hart
Stroke 39:1901-10. 2008..Additional research to identify an optimum scheme for primary prevention and subsequent standardization of recommendations may lead to more uniform selection of patients for anticoagulant prophylaxsis...
Genetic testing for warfarin dosing? Not yet ready for prime timeHenry I Bussey
Pharmacotherapy 28:141-3. 2008
Risk of thromboembolism with short-term interruption of warfarin therapyDavid A Garcia
Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
Arch Intern Med 168:63-9. 2008..We aimed to assess the frequency of thromboembolism and bleeding within a large cohort of patients whose warfarin therapy was temporarily withheld for an outpatient invasive procedure...
Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillationElaine M Hylek
Europace 10:3-5. 2008
Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation studyMargaret C Fang
University of California at San Francisco, 94143, USA
J Am Geriatr Soc 54:1231-6. 2006..To assess whether older age is independently associated with hemorrhage risk in patients with atrial fibrillation, whether or not they are taking warfarin therapy...
Death and disability from warfarin-associated intracranial and extracranial hemorrhagesMargaret C Fang
The Department of Medicine, Hospitalist Group, University of California, San Francisco, Calif 94143, USA
Am J Med 120:700-5. 2007..We examined the rates of death and disability resulting from warfarin-associated intracranial and extracranial hemorrhages in a large cohort of patients with atrial fibrillation...
Paracetamol (acetaminophen) and warfarin interaction: unraveling the pivotal role of the vitamin K cycleElaine M Hylek
Thromb Haemost 92:672-3. 2004
